Pharmaceutical manufacturers have welcomed health minister Aaron Motsoaledi’s announcement of a 3.78% private-sector medicine price increase for 2019. Medicine prices in the private sector are tightly controlled by the health department, which usually permits one increase a year on the ceiling price for each drug. While pharmaceutical manufacturers can freely determine the launch price of their products, from that point on they may not increase their private-sector prices beyond an annual threshold set by the minister, known as the single exit price. “The single exit price has been quite a controversial issue. This is welcome because it brings us closer to inflation and is likely to be implemented in January,” said pharmaceutical task group spokesperson Stavros Nicolaou. “It is more closely aligned to trading conditions and its more timeous implementation will assist the difficult environment and also reduce administrative burden in the sector, per President Cyril Ramphosa’s call to...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now